Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506441 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
A Phase 3 study, sponsored by Tanabe Pharma Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
NCT00506441 is a Phase 3 study that has completed, run by Tanabe Pharma Corporation. The registered enrollment target is 245 participants.
The verdict
NCT00506441, a Phase 3 study, has completed, sponsored by Tanabe Pharma Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
Study Summary
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.
Interventions
- DRUG Placebo
- DRUG MCI-196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00506441
The ClinicalTrials.gov registry entry for NCT00506441 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00506441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00506441 about?
NCT00506441 is a clinical study titled "A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia". This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.
What is the current status of trial NCT00506441?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2007-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00506441?
The interventions under investigation include: Placebo (DRUG), MCI-196 (DRUG).
Who is sponsoring clinical trial NCT00506441?
This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.